Adicet Bio is a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
Adicet Bio was founded in 2014 by Aya Jakobovits.
1282 health care and life sciences companies are in the directory, 165 of them in the same 101-250 employee range and 43 based in San Francisco Bay Area.
Adicet Bio may be growing as indicated by several financial activities and market responses. A director from Orbimed Advisors Llc acquired a significant number of shares, specifically 3125000 shares, which could suggest confidence in the company's prospects and stability. Additionally, the company's stock has been given an average rating of 'Moderate Buy' by analysts, reflecting a positive market sentiment towards Adicet Bio. Furthermore, the estimated fair value of the company's stock is reported to be US$5.96 based on a 2 Stage Free Cash Flow to Equity model, which may imply that the current stock price is undervalued, potentially attracting more investors.
“Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.” adicetbio.com
Founded in 2014, Adicet Bio works in biopharma, biotechnology and health care from San Francisco Bay Area and has 101-250 employees. It has raised $243.6 million over 5 rounds and its website drew about 1,885 visits in the latest month measured.
501-1,000 employees · adaptimmune.com
101-250 employees · aveooncology.com
51-100 employees · adelabio.com
51-100 employees · als.net
51-100 employees · aoporphan.com
51-100 employees · acutis.com
51-100 employees · abingdonhealth.com
251-500 employees · accelgen.com
11-50 employees · alxoncology.com
11-50 employees · 3tbiosciences.com
Data sources: company facts, funding and leadership from Crunchbase; website traffic estimates from Semrush (latest month); company website, checked 2026-11-10; industry codes from the US NAICS and SIC lists; comparisons calculated from the profiles in this directory.